Exclusive Online Content
Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat & Prevent SARS-CoV-2 Infections
Pardes Biosciences, Inc. recently announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral….
Jasper Health & BioIntelliSense Form Strategic Collaboration to Transform Remote Monitoring for Oncology Care
Jasper Health recently announced it has formed a strategic collaboration with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to integrate its medical grade….
Fusion Antibodies Partners With Eurofins Discovery to Support Innovative Preclinical Drug Discovery Research
Fusion Antibodies plc recently announced it has entered into a commercial collaboration with Eurofins, a Eurofins Scientific SE (EUFI.PA) group company; a leading provider of products and services to the….
Adhera Therapeutics Signs Exclusive License Agreement With Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate
Adhera Therapeutics, Inc. recently announced it has executed an exclusive license agreement with Melior Pharmaceuticals I, Inc. defining the terms and conditions for which Adhera will license MLR-1023….
Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility
Quotient Sciences, the drug development and manufacturing accelerator, recently announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, UK…..
Aptamer Group & Bio-Works Technologies Partner to Enable Improved Solutions for Gene Therapy Manufacturing
Aptamer Group Ltd and Bio-Works Technologies AB recently announced they have entered into an agreement to co-develop a new affinity resin for improved purification and scale up of….
Shape Therapeutics Enters Strategic Research Collaboration With Roche to Advance Breakthrough AAV-Based RNA Editing Technology for Neuroscience & Rare Disease Indications
Through this partnership Shape will apply its proprietary RNA editing platform RNAfix and potentially leverage its AAVid technology platform for next-generation tissue-specific adeno-associated viruses (AAVs) for the development of gene therapy for….
Vifor Pharma & Cara Therapeutics Announce US FDA Approval of Injection for Treating Moderate-to-Severe Pruritus in Hemodialysis Patients
Cara Therapeutics and Vifor Pharma recently announced the US FDA has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with….
SomaLogic & Twist Bioscience Corporation Announce Partnership to Discover Novel Therapeutic Targets & Antibodies
CM Life Sciences II and SomaLogic, Inc., and Twist Bioscience Corporation recently announced a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on….
Vyant Bio & Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
Vyant Bio, Inc. and Cyclica, Inc. recently announced a non-exclusive strategic collaboration combining Vyant Bio’s patient-derived complex organoid biology alongside Cyclica’s….
EXCLUSIVE ONLINE CONTENT
SomaLogic Announces Strategic Collaboration With UPMC to Tailor Clinical Care Through Proteomics Technology
SomaLogic recently announced a strategic collaboration with leading health system UPMC to explore how the large-scale study of proteins and….
ProQR Announces Axiomer RNA Editing Licensing & Research Collaboration With Lilly
ProQR Therapeutics N.V. recently announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and….
Longeveron Partners With Kinesiometrics to Create & Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy
Longeveron Inc. has entered into an agreement with Kinesiometrics Inc., to provide a cutting-edge, digital data-driven solution for objective real-time measurement of functional capacity and quality….
AzurRx BioPharma Announces Acquisition of First Wave Bio & its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
AzurRx BioPharma, Inc. recently announced it has entered a definitive agreement to acquire First Wave Bio, Inc. in a stock and cash transaction valued at….
ABITEC Corporation & Larodan AB Announce Brand Refresh After Successful Integration of the Two Companies
ABITEC Corporation, an ABF Ingredients company, recently announced in July 2020 the acquisition of Swedish manufacturer and international marketer of state of the art, high-purity research grade lipids, Larodan AB….